Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (NAICS 33451)

A Histometrics rollup primer for public-market and private investors. This synthesizes nine already-written child-industry primers plus our ground-truth federal statistics for this level. Figures are reported facts with citations; statements about the future are labeled outlook or judgment.

1. Overview

This is the U.S. instruments industry: the plants that build the machines that sense, measure, test, image, guide, and control the physical and biological world. NAICS 33451 — NAICS is the North American Industry Classification System, the federal scheme for grouping businesses — gathers nine distinct sub-industries under one roof, from pacemakers and MRI (magnetic resonance imaging) scanners, to fighter-jet radar and missile guidance, to the thermostat on your wall, the flow meter in a refinery, the water meter on your house, the oscilloscope on an engineer's bench, the mass spectrometer in a drug lab, the CT (computed tomography) scanner and cancer-treatment accelerator in a hospital, and the radiation detector in a nuclear plant.[1]

Why an investor should care: taken together these are the "picks and shovels" of the entire economy and the health system. Almost nothing gets designed, manufactured, treated, transported, defended, or billed without one of these instruments verifying it first. That gives the level three shared traits worth owning: (1) high-value, engineering-intensive products protected by patents and hard-won certifications; (2) razor-and-blade recurring revenue — the money is less in the box than in the decade-long tail of consumables, service, calibration, spares, software, and replacement that follows an installed base; and (3) diversification across cycles — defense, health care, industrial capital spending, utilities, semiconductors, and construction all pull different levers, so the aggregate is steadier than any single piece.[1]

The real story of this level is the contrast among its nine children (Section 2). They differ enormously in size (from a ~$54 billion defense-electronics giant down to a ~$3 billion controls niche), in growth direction, in how concentrated they are, in the gross margins they earn (roughly 32% to 69%, Section 5), and in who owns them — from S&P 500 defense primes and medical-device blue chips to private German family firms, private-equity roll-ups, and venture-backed disruptors. No single ticker or fund captures the whole thing; the practical route in is child-by-child.

2. What's inside — the nine children and how they differ

All nine are "instruments," but they serve different customers and behave differently as businesses. The table contrasts them on the dimensions that matter to an investor. Receipts are 2022 factory shipments; "share" is of this level's $168.6 billion. CR4 is the top-four firms' share of receipts; HHI is the Herfindahl-Hirschman Index (a 0–10,000 concentration score — under 1,500 is "unconcentrated" by U.S. antitrust standards). Direction of travel is our synthesis of the child primers' outlooks (forward-looking judgment).

How to read the contrast:

• Two "defense-and-big-iron" children stand apart on HHI — but a third is top-heavy in a different way. Navigation/radar/guidance (334511) and irradiation apparatus (334517) are the only two in the "moderately concentrated" band (HHI 1,200 and 1,574), with top-four shares of 57.9% and 67.5% and top-twenty shares of 90.6% and 93.4%.[3][9] But the smallest child, environmental controls (334512), now has the third-highest CR4 in the level at 40.8% despite a benign HHI of 603 — and its concentration has roughly doubled in two decades, from a CR4 of 24.8% and an HHI of 238.1 in the 2002 Census.[4] Concentration in this level is a moving target, not a fixed structural fact.
• "Fragmented" is misleading everywhere. Each low-HHI child pools several unrelated product niches, and within a niche the structure is a tight two- or three-brand oligopoly: semiconductor automated test equipment is an ~80% two-firm duopoly;[7] the top five vendors hold ~96% of the U.S. medical-imaging market, with one at ~40%;[9] six firms hold roughly 80% of hearing aids;[2] surveying is effectively three names.[10] The aggregate codes look open; the real markets are not (Section 8).
• Size ≠ number of firms. The single largest child (334511) has just 404 firms; the fifth-largest (334519) has 789. Value concentrates in the defense/health children; headcount and firm-count in the industrial/measurement children.
• Pay and output per worker vary two-fold across the children. Average pay runs from ~$82,000 in metering to ~$87,000–90,500 in process control, the catch-all, and environmental controls, up to ~$112,000–121,000 in defense electronics, analytical labs, electromedical, and irradiation.[2][3][4][5][6][8][9][10] Output per worker spans ~$443,000 in metering to ~$730,000 in irradiation.[6][9] The health and defense children are the high-value end of an already high-value sector.
• Ownership runs the full spectrum. From deep public franchises (medical devices, defense primes, life-science tools) to industries where the best names are private or foreign — process control's Endress+Hauser, KROHNE and VEGA; electrical test's Rohde & Schwarz; meters' Diehl, Kamstrup and Master Meter; controls' Danfoss, Bosch and Belimo; labs' Metrohm, LECO and Anton Paar; materials testing's ZwickRoell; radiation detection's Ludlum — to the catch-all (334519), which is "overwhelmingly private."[4][5][6][7][8][10]
• Direction of travel is genuinely divergent — and one child has split in two. Defense electronics is in a clear up-cycle; the health-care children grow steadily and defensively; analytical labs are muted but showing early recovery; process control is cyclical with an intact structural case; environmental controls is mid-transition. Electrical test is now the outlier: within one child, semiconductor test grew 18.8% in 2025 on AI demand while a major general-purpose test business fell 14.5% and wrote off $1.44 billion of goodwill tied to electric-vehicle exposure.[7] Owning the level is owning that spread.
• A vintage caveat on the receipts column. Two children now lead with newer Annual Integrated Economic Survey (AIES) 2023 figures that run well above the 2022 Economic Census: electromedical at $45.5 billion versus $39.6 billion, and environmental controls at $4.196 billion versus ~$3.0 billion.[2][4] The table above stays on the 2022 Census throughout because that is the only vintage available for all nine and for the level total — mixing vintages would break the shares. Read the newer figures as evidence that the 2022 baseline is conservative, not as replacements for it.

3. How big it is — the rollup

Our ground-truth federal statistics for the whole level:

On a like-for-like 2022 Census and 2023 CBP basis, the nine children still add up cleanly: their receipts sum to ~$168.7 billion, their employment sums exactly to 414,694, and their establishments sum exactly to 5,050 — confirming these are the complete set.[1][2][3][4][5][6][7][8][9][10] (Firm counts don't sum: the children total ~4,581 firms against 4,427 at the level, because a company active in two child industries is counted once here but appears in each child.) Note one wrinkle from the revised children: the electromedical primer now reports employment of 94,349 from AIES 2023 rather than the 94,361 CBP figure that makes the level sum work.[2] The two come from different Census programs with different reference periods and reporting units; the rollup arithmetic above holds only on the CBP basis.

The economics are the signature of a capital- and intellectual-property-intensive sector: ~$407,000 of output and ~$106,000 of pay per worker, well above the manufacturing average — value comes from engineering and certification, not headcount.[1]

The undercount caveat — read this before quoting $168.6 billion. This figure is what U.S. establishments physically ship, not the size of the business the household-name companies actually run, and the revised children make the gap vivid:

1. The giants are booked under other codes — and single segments now rival whole children. GE HealthCare's global Imaging segment alone generated about $9.2 billion in 2025 — essentially the entire irradiation child's $9.18 billion of U.S. shipments.[9] Honeywell's Building Automation segment booked $7.367 billion in 2025 at a 22.1% margin, more than twice the environmental-controls child's ~$3.0 billion (that segment is global and also carries fire, security, and services).[4] Thermo Fisher's Analytical Instruments segment was $7.55 billion against the whole analytical child's $19.35 billion, and Keysight books $5.4 billion worldwide against the whole electrical-test child's $11.66 billion.[7][8] Medtronic, Abbott, and Boston Scientific book most sales under other medical codes; radar and guidance dollars are largely counted inside aircraft (NAICS 336411) and guided-missile/space (336414) manufacturing.[2][3] (The two child primers cite slightly different GE HealthCare 2025 company totals — $20.3 billion and $20.6 billion — from the same filing; the segment figure is consistent.)
2. Trade cuts both ways, and not uniformly by child. The parent's old blanket claim that "imports aren't in it" is only half right. Controls, meters, imaging systems, and test gear are heavily import-supplied (Siemens Healthineers, Philips, Endress+Hauser, Rohde & Schwarz, Advantest, Diehl, Kamstrup), so U.S. shipments understate U.S. consumption there.[4][5][7][9] But in electromedical the flow runs the other way: U.S. receipts of $45.5 billion (AIES 2023) exceed an estimated U.S. domestic market of about $26.3 billion in 2024, because America is a net exporter of high-end implants and devices — even though the broader medical-instruments trade line (HS 9018) ran $35.8 billion of exports against $41.3 billion of imports in 2024.[2] Treat the level as a mix of net-export and net-import children, not one import-swamped whole.
3. Global sales dwarf U.S. output, including at firms with no U.S. listing. Privately held Endress+Hauser passed €4 billion of 2025 sales with 18,306 employees; privately held Rohde & Schwarz booked €3.16 billion in fiscal 2024/25; Elekta's fiscal 2025/26 net sales were SEK 16.7 billion (~$1.7 billion).[5][7][9] None of that is U.S. shipments.
4. The recurring streams sit elsewhere. Consumables, service, calibration, and software subscriptions are frequently classified as services, not manufacturing. GE HealthCare split 2025 into $13.7 billion of product and $7.0 billion of service — and ended the year with $10.7 billion of service remaining performance obligations against $5.0 billion of product obligations.[2] Keysight's services reached 24% of revenue; Agilent's 29%.[7][8] Almost none of that annuity lands in this manufacturing line.

A note on ownership and undercount: unlike some industries, this one is not materially undercounted by missing small proprietors — it is a corporate, incorporated sector of mostly substantial firms. Even "small" here means something unusual: the SBA thresholds across the nine children run from 600 to 1,350 employees,[11] and the FDA's own analysis of the irradiation child found that 98 of its 113 employer firms (87%) qualified as small under a 1,200-employee cutoff.[9] The small/family-owned long tail is real but concentrated in the catch-all (334519), environmental controls (334512), and process instruments (334513), and it does not distort the totals much. The undercount here is a code-structure problem — diversified giants booked elsewhere, plus trade flows and global sales — not a hidden-informal-economy problem.

4. The investable universe — where value concentrates

There is no single "instruments" stock and no ETF (exchange-traded fund) for NAICS 33451. Value concentrates in three places, and the practical map is child-by-child:

• The defense-electronics child (334511) and the health-care children (334510, 334517) hold the biggest, cleanest public franchises. Defense: RTX, Lockheed Martin, Northrop Grumman, General Dynamics, L3Harris, Honeywell for the primes, with a focused mid-cap tier — Teledyne (TDY), Leonardo DRS (DRS), Curtiss-Wright (CW), Kratos (KTOS), Mercury Systems (MRCY), and Garmin (GRMN) for civil avionics — where a larger share maps to the code; aerospace-and-defense funds (ITA, PPA, XAR) reach the whole complex in one click.[3] Medical: Medtronic (MDT), Abbott (ABT), GE HealthCare (GEHC), Boston Scientific (BSX), Johnson & Johnson (JNJ), plus focused names Dexcom (DXCM), Masimo (MASI), and iRhythm (IRTC), reachable in bulk through IHI and XHE.[2] Imaging and radiation therapy add GE HealthCare again plus Varex Imaging (VREX), Accuray (ARAY), OSI Systems (OSIS), Hologic (HOLX), Dentsply Sirona (XRAY), and Sotera Health (SHC) for the cobalt-60 franchise.[9]
• The industrial/measurement children (334513, 334515, 334516, 334519, 334514, 334512) are dominated by diversified serial acquirers where instruments are one segment — Emerson (EMR), Honeywell (HON), AMETEK (AME), Fortive (FTV) and its 2025 spin-off Ralliant (RAL), Roper (ROP), Danaher (DHR), Thermo Fisher (TMO), Agilent (A), Illinois Tool Works (ITW), Amphenol (APH), Rockwell (ROK), Xylem (XYL), Hubbell (HUBB), and Johnson Controls (JCI), Carrier (CARR), Trane (TT), Lennox (LII) on the controls side. A widening set of near-pure-plays gives focused exposure: Keysight (KEYS), Teradyne (TER), VIAVI (VIAV) and NetScout (NTCT) in test; Waters (WAT), Mettler-Toledo (MTD), Bruker (BRKR) and Revvity (RVTY) in labs; Badger Meter (BMI), Itron (ITRI) and Mueller Water (MWA) in meters; Mirion (MIR) and Vishay Precision Group (VPG) in detection and precision sensing; Trimble (TRMB) in surveying; Resideo (REZI), Generac (GNRC) and Watts Water (WTS) in controls; MKS Instruments (MKSI) in process/semiconductor instruments.[4][5][6][7][8][10] One brand caveat: the child primers disagree on whether the Fluke franchise stayed with Fortive or moved to Ralliant in the June 2025 separation — treat the split of test brands between those two tickers as unsettled until you check the filings.[7][10]
• The best franchises you often can't buy publicly. Several category leaders are private or foreign-listed: Rohde & Schwarz (test, private German), Endress+Hauser, KROHNE and VEGA (process, private), Diehl, Kamstrup and Master Meter (meters, private), Belimo (near-pure-play controls, Swiss-listed), Danfoss and Bosch (controls, private), Metrohm, LECO and Anton Paar (labs, private/foundation-owned), ZwickRoell (materials testing, private German), Ludlum (radiation detection, family-owned), Campbell Scientific and Timex, BIOTRONIK (cardiac, private German), Copeland (controls, Blackstone-owned), plus foreign-listed majors Siemens Healthineers, Philips, Advantest, Anritsu, Yokogawa, Elekta, IBA, Hexagon, Topcon, Spectris, Shimadzu, Horiba, Sartorius, ABB, Siemens, and Schneider Electric.[2][4][5][6][7][8][9][10]

The through-line: public-market access is deepest in defense and health care, and shallowest in the industrial-measurement middle, where you either buy a diversified conglomerate or reach for a scarce pure-play — though the breakup wave described in Section 8 is steadily manufacturing new pure-plays. Tickers, prices, dividend yields, and valuation multiples belong to this section and Section 10 by design — elsewhere this is a manufacturing sector, not a stock list.

5. How the money works

Despite nine different end-markets, the children share one economic engine that is worth understanding as a single model:

• Razor-and-blade recurring revenue is the prize. In every child, the initial device sale seeds a multi-year, higher-margin annuity: implant replacements and CGM (continuous glucose monitor) sensors in electromedical; radar spares and upgrades in defense; chromatography columns, reagents, and service in analytical labs; calibration, spares, and software in test and measurement; smart-meter network software in metering; X-ray tubes (replaced every two to six years in CT) and cobalt-60 source replenishment (a 5.3-year half-life) in irradiation; SaaS building-analytics in controls.[2][3][6][8][9] The hard numbers now line up across children: recurring revenue is 80%+ of sales at the largest analytical makers (~83% at Thermo Fisher, ~81% at Danaher), Waters books $632 million of consumables and $1.19 billion of service against $1.35 billion of instruments, GE HealthCare's service backlog is more than double its product backlog, and Mirion draws over 80% of its nuclear-power revenue from its installed base.[2][8][10]
• The gross-margin ladder tracks how much of the value is not the box. Across the level, gross margins run from roughly 32% to 69%, and the ordering is the thesis: implantables and monitoring at the top (Boston Scientific ~69%, Dexcom ~60%), high-end test and precision metrology next (Keysight 62.1%, FARO 54.7%), lab instruments behind them (Mettler-Toledo ~58%, Agilent 52.4%), then detection and metering (Mirion ~47%, Badger Meter ~41.7%), capital imaging around 40%, and OEM radiation hardware at the bottom (Varex 34.4%, OSI Systems 34.3%, Accuray 32.1%).[2][6][7][8][9][10] Itron shows the same ladder inside one company: 31.2% gross margin on Device Solutions, 39.1% on Networked Solutions, 39.6% on Outcomes analytics.[6] That single comparison is the cleanest evidence in the level that value is migrating from hardware to the network and software around it.
• Installed base + switching costs = pricing power. Once an instrument is "specified" into a plant, hospital, ship, or lab — and validated for a regulated workflow — replacing it means re-qualifying, re-certifying, and re-training. That lock-in protects pricing across all nine children, and it shows up in the price line: the producer price index for process-control instruments rose 6.7% between April 2025 and April 2026.[5][8]
• High R&D intensity is the moat. Winners plow roughly 6–19% of sales back into R&D (research and development); a missed performance generation loses design sockets for years. The revised children put medtech lower than previously assumed (GE HealthCare ~6%, Medtronic ~8.5%, Boston Scientific ~10%) and test higher (12–18% typical, Keysight at 19%), with analytical tools at ~8–12% (Anton Paar 14.5%), irradiation at 10.8–12% (Varex, Elekta), and process control at 7.0% (Endress+Hauser).[2][5][7][8][9]
• Backlog and book-to-bill are the forward gauges. For the capital-goods children (defense, process control, test, irradiation, meters, materials testing), orders are booked ahead of shipment; a book-to-bill ratio above 1.0 signals expanding backlog and revenue. Defense-electronics suppliers ran about 1.1x with record backlogs in 2024; Itron entered 2025 with roughly $4.7 billion of backlog; Mirion's remaining performance obligations rose to $1.1 billion from $812 million.[3][5][6][7][10] One caution the children add: backlog is not revenue — customers can often cancel or reschedule without penalty.[10]
• Operating margins spread wider than gross margins. The best segments clear the mid-20s to low-30s (Abbott Medical Devices 33.7%, Garmin aviation 26%, Curtiss-Wright Defense Electronics 24.7%, Emerson Intelligent Devices 23.8%, Thermo Fisher Analytical Instruments 23.0%, Honeywell Building Automation 22.1%); the middle sits in the mid-teens to low-20s (Agilent 21.3%, Badger Meter ~20%, Rockwell Intelligent Devices 18.0%, Keysight 16.3%, RTX Collins 16.3%); and the bottom clusters near 12% (Itron 13.2%, Elekta 12%, Endress+Hauser 11.9%, Xylem's metering segment 11.7%).[2][3][4][5][6][7][8][9] Some participants lose money outright — Varex posted a $70 million net loss in fiscal 2025 despite growing sales.[9]
• What varies is the customer and the cycle. The payer differs — CMS and private insurers (medical), the Pentagon (defense), utilities and their rate regulators (meters, some controls), industrial capital budgets (process, test), and pharma/academic budgets (analytical). That is exactly why the aggregate is diversified: the recurring-revenue model is common, but the demand triggers are not.

6. What drives demand

Because the level is a portfolio of nine niches, its demand is a portfolio of separate drivers rather than one cycle — a key reason to think of it as a diversified basket:

• Defense budgets and the threat environment drive 334511 (and part of 334519): about $900.6 billion for national defense in FY2026, of which roughly $295 billion is procurement plus RDT&E — the buckets that buy sensors and guidance, with the NDAA authorizing $161.7 billion of procurement and $145.7 billion of RDT&E.[3] Sensors, missile defense, counter-drone, and electronic warfare are priority accounts, and a new driver has emerged: DHS's 2025 guidance urging resilient positioning, navigation and timing against GPS jamming and spoofing.[3]
• Demographics, chronic disease, and cancer care drive the health children (334510, 334517, part of 334516): the U.S. population aged 65 and over reached 61.2 million in 2024 (18.0% of the population, up 3.1% in a year), total adult diabetes prevalence was 15.8% in 2021–2023, and the National Cancer Institute estimates 2.1 million new U.S. cancer cases in 2026.[2][9] CMS projects national health expenditures to grow 5.4% annually through 2034, reaching 20.6% of GDP.[2]
• Industrial and energy capital spending drives 334513 and part of 334515/334519: process industries are 55–60% of instrumentation demand, with LNG (liquefied natural gas), grid build-outs, and refinery/chemical capex as swing factors — offset near-term by disciplined oil-and-gas budgets and a U.S. semiconductor-fab construction slowdown from the 2024 peak.[5]
• Semiconductors and AI are the loudest current driver for 334515 and part of 334513/334516: more complex chips need more sophisticated testing, and Teradyne's Semiconductor Test revenue rose 18.8% in 2025, primarily on AI-related compute demand.[7] Data-center construction is now a distinct demand line of its own — Belimo reported that data-center cooling contributed just under half of its 2025 sales growth.[4]
• Utility capital budgets and infrastructure funding drive 334514: North American water AMI (advanced metering infrastructure) penetration was still only about one-third at end-2022 (~38 million AMI endpoints of ~86.5 million automated), against an EPA-assessed $625 billion of 20-year drinking-water need and $50 billion-plus of federal water money including $15 billion for lead service lines.[6]
• Construction, energy efficiency, and electrification drive 334512: heat-pump adoption, tighter building codes, the A2L refrigerant transition mandating new sensor content, and grid demand-response. The Department of Energy estimates high-performance building controls can cut commercial HVAC energy use by 30%, and that nationwide deployment would cut total U.S. energy consumption by more than 3% — across 5.9 million commercial buildings spending $141 billion a year on energy.[4]
• Pharma/biotech R&D and research funding drive 334516: biologics, GLP-1 drugs, cell-and-gene therapy, and PFAS ("forever chemicals") testing — EPA Methods 533 and 537.1 together cover 29 PFAS compounds by LC-MS/MS. NIH's FY2025 appropriation was $48.5 billion, with $35.3 billion awarded through grants.[8]
• Nuclear revival tied to AI data-center power is a fresh driver for 334519 (radiation detection): technology companies have committed over $10 billion to nuclear partnerships, and the radiation detection, monitoring and safety market is projected to grow from $3.38 billion in 2024 to $5.45 billion by 2030 (8.3% CAGR).[10]
• Security and sterilization add two more: airport and cargo screening budgets underpin security X-ray/CT, and the regulatory push away from ethylene oxide (roughly half of U.S. device sterilization today) toward electron-beam and X-ray irradiation should roughly double the irradiation-sterilization-services market that buys those machines, from $2.08 billion in 2022 to $4.59 billion by 2030.[9]

Cutting across all of them: replacement and calibration cycles generate steady demand largely independent of the business cycle, and technology jumps (photon-counting CT, AI-enabled diagnostics, connected/wearable devices, smart meters, software-defined sensors) pull replacement demand forward.

7. Regulation

Across this level, regulation is more often a moat and demand creator than a constraint — certification is the ticket to play, and rules force customers to buy more instruments. The common threads:

• Metrological traceability to NIST (the National Institute of Standards and Technology) underpins the measurement children (334513, 334514, 334515, 334519): results must trace through an unbroken calibration chain to national standards, and accredited calibration (ISO/IEC 17025) is itself a recurring-revenue business. For billing-grade meters, NIST Handbook 44 (2026 edition) plus NTEP type evaluation and state weights-and-measures approval set the bar.[5][6][7][10]
• FDA (Food and Drug Administration) device rules gate the health children (334510, 334517): risk-class pathways — 510(k) clearance, PMA (premarket approval), De Novo, Breakthrough Devices — plus, for irradiation, dual radiation-safety regulation (21 CFR 1000–1050) and the Mammography Quality Standards Act.[2][9] Two frontiers are new and common to both children: section 524B cybersecurity requirements for "cyber devices" in force since March 29, 2023, and the Quality Management System Regulation (QMSR), effective February 2, 2026, which incorporates ISO 13485:2016 and opens management-review, quality-audit, and supplier-audit records to FDA inspection.[2][9] Getting paid is a second gate, run through CMS (the Centers for Medicare & Medicaid Services) via NTAP, the TCET pathway, and the newer RAPID program — all aimed at shortening the gap between approval and revenue.[2]
• Cybersecurity has become a regulated requirement in four of the nine children, which the old parent treated only as a risk. Beyond FDA §524B, defense suppliers must satisfy DFARS 252.204-7012 and the CMMC framework and flow them down to subcontractors; process control is pulled toward IEC 62443, with CISA warning on operational-technology exposure; and water metering faces GAO findings on incomplete risk assessment, with 73% of AWWA's 2025 survey respondents rating cybersecurity very-to-critically important.[2][3][5][6]
• Export controls — ITAR (International Traffic in Arms Regulations) and EAR (Export Administration Regulations) — bind defense electronics (334511), high-end test gear (334515), and precision/nuclear instruments (334519), where NRC licensing under 10 CFR Part 110 adds months to more than a year for nuclear-related equipment.[3][7][10] Advanced-chip controls directly gate who can buy the most sophisticated semiconductor testers.[7]
• Functional-safety, environmental, and metrology standards create demand in process control (IEC 61511 safety-instrumented systems, EPA continuous-emissions monitoring, and the March 2024 EPA oil-and-gas methane rule permitting continuous methane monitoring), metering (NSF/ANSI/CAN 61 and 372 lead-free certification, AWWA C700 accuracy standards), labs (21 CFR Part 11, USP <1058> instrument qualification, ICH Q2 method validation), and controls (ENERGY STAR, DOE efficiency standards, the AIM Act HFC phasedown and its A2L leak-detection requirements).[4][5][6][8]
• Nuclear licensing (NRC) raises barriers in irradiation (cobalt-60 sources, Agreement-State oversight) and radiation detection (ASME NQA-1, 10 CFR 50 Appendix B quality programs) — while the NNSA's Cesium Irradiator Replacement Project actively pushes hospitals from sealed cesium sources toward X-ray machines.[9][10]
• Fiscal and domestic-content policy now cuts both ways. The 25C residential efficiency credit expired for equipment placed in service after December 31, 2025 and the 179D commercial deduction terminates for construction beginning after June 30, 2026 — near-term headwinds for controls.[4] And a Build America, Buy America nonavailability waiver keeps federally funded AMI water-meter projects buildable only through December 19, 2027, after which domestic-content sourcing becomes a live constraint.[6]

The net effect is uniform: certification raises barriers to entry, protecting incumbents, while simultaneously creating approval, recall, and compliance-cost risk for any single product line.

8. Consolidation

Three patterns run across the whole level, and the same acquirer names recur — a defining rollup insight.

Pattern 1 — the aggregate looks unconcentrated, but every child is more concentrated than the parent. The level's HHI of 163.2 is lower than any individual child's, its CR4 of 19.0% is lower than the lowest child's (23.5%), and every child for which Census publishes a top-50 share sits above the level's 58.9% — up to 96.2% in defense electronics and 93.2% in metering.[1][3][6][10] This is arithmetic, not competition: the code pools nine industries that don't compete with one another. In reality, pacemakers and hearing aids (334510), high-end imaging and radiation oncology (334517), semiconductor test (334515 — an ~80% two-firm duopoly), mass spectrometry (334516), and surveying and materials testing (334519) are each controlled by two or three names.[2][7][8][9][10]

Pattern 2 — the same serial acquirers straddle multiple children. A short list of diversified industrials rolls up niche after niche: Emerson (process control, environmental controls, and — via National Instruments — electrical test), Honeywell (controls, process solutions, and gas meters), AMETEK and Fortive/Ralliant (process, electrical, metrology, and other measurement), Roper, Xylem and Hubbell (flow and metering), Danaher and Thermo Fisher (analytical labs), ITW and Amphenol (materials testing and precision sensors), and GE HealthCare and Siemens Healthineers (electromedical and irradiation).[2][4][5][6][7][8][9][10] Recent landmark deals show the scale: Waters and BD's Biosciences & Diagnostic Solutions business combined in a ~$17.5 billion Reverse Morris Trust that closed February 9, 2026; J&J–Shockwave (~$13.1 billion); Siemens–Varian (~$16 billion); Blackstone–Copeland (~$14 billion); Emerson–National Instruments (~$7.8 billion, not the $8.2 billion previously carried here) and Emerson's completed AspenTech buy-in in March 2025; AMETEK–FARO (~$920 million, July 2025); Teradyne's purchase of Infineon's ATE division (2025); and Generac–ecobee (up to ~$770 million).[2][4][5][7][8][9][10]

Pattern 3 — and this is new — the level is now splitting apart as fast as it consolidates. The same conglomerates that spent thirty years rolling these niches up are breaking them back out into purer plays: Honeywell into three companies (Solstice Advanced Materials in 2025, Aerospace targeted for 2026, leaving an automation core); Fortive spinning Ralliant in June 2025; Danaher spinning Veralto in 2023; GE spinning GE HealthCare in 2023; Varian spinning Varex in 2017; Johnson Controls selling residential and light-commercial HVAC to Bosch for ~$8.1 billion in 2025; Xylem selling its non-North-American metering arm to AURELIUS in 2025.[4][5][7][8][9] Private equity has become a first-class owner class alongside the strategics — Blackstone in Copeland, New Mountain in the former PerkinElmer applied platform (up to $2.45 billion), Arcline's DwyerOmega roll-up, Veritas in Frontgrade, plus take-privates of EXFO and Natus.[3][4][5][7][8] For investors this creates three repeatable plays across every child: own the acquirers for compounding scale, own or back the innovators as acquisition targets, and buy the spin-offs when a conglomerate finally surfaces a pure instrument business — though the Ralliant example (a $1.44 billion goodwill impairment in its first full year) is a reminder that a newly focused pure-play concentrates the downside as well as the upside.[7]

9. Risks

• Cyclicality of capital spending. The industrial-measurement children rise and fall with customer capex; semiconductor test is the most violent. Concrete recent evidence: Ralliant's test-and-measurement sales fell 14.5% in 2025 and carried a $1.44 billion impairment; Keysight's revenue dropped 9% in 2024 with GAAP operating margin falling from 24.8% to 16.7%; Agilent's revenue declined 5% in fiscal 2024 before rebounding 7%; FARO's sales fell 4.6% in 2024 on weak China and U.S. demand.[5][7][8][10]
• Budget, reimbursement, and policy risk. Different children depend on different public payers — Pentagon appropriations, CMS coverage and payment rates (a 2025 CMS proposal would subject continuous glucose monitors to competitive bidding), utility rate cases, and research funding (a 2025 move to cap NIH indirect costs near 15% plus billions in grant terminations).[2][3][8] Add three dated policy cliffs: the 25C credit's expiry after 2025, 179D's termination for construction begun after June 30, 2026, and the AMI water-meter BABA waiver's expiry in December 2027.[4][6]
• Tariffs are now a quantified, level-wide margin headwind, not a hypothetical. GE HealthCare estimated tariffs cut its 2025 operating income by approximately $245 million and cash flow by approximately $285 million; Siemens Healthineers and Philips each projected impacts of hundreds of millions of euros; Keysight cited tariffs among the factors that held its margin flat despite an 8% revenue recovery; Varex says tariffs raised material costs and made U.S.-produced equipment less competitive abroad; Emerson, Rockwell, Mirion and Carrier all flag tariffs in their filings.[2][4][5][7][9][10]
• Supply-chain pinch points are specific and hard to substitute. Semiconductors, rare earths, gallium and germanium, cobalt, tantalum, rhenium and titanium (defense); helium, iodine and rare-earth minerals (imaging); cobalt-60 on reactor harvest schedules and sole-source detector materials (irradiation); 20-year lithium batteries and brass (metering); custom sole-sourced ICs (test).[2][3][6][7][9] The recurring problem is qualification: swapping a component can require redesign, revalidation, and sometimes a new regulatory submission, and re-qualifying a material can take up to twelve months.[9][10]
• Customer concentration. Varex's five largest OEM customers were about 40% of fiscal 2025 revenue, with one at 18%; Teradyne states its test demand is concentrated among a limited number of significant customers; defense suppliers concentrate on a single sovereign buyer.[3][7][9]
• Fixed-price and long-contract execution. L3Harris booked 73% of fiscal 2024 revenue on fixed-price contracts, and RTX took a $600 million charge on the termination of a foreign fixed-price development contract — the classic way this level converts an engineering slip into an earnings miss.[3]
• Technology disruption and structural decline. Software, AI, autonomy, and at-home/wearable formats can obsolete installed hardware; low-cost sensing and open data formats can commoditize the box.[3][10] One child shows what the downside looks like when it runs for two decades: environmental-controls employment fell 63.5% between 2000 and 2024, from 35,549 to 12,965.[4]
• Foreign and low-cost competition. Well-capitalized non-U.S. leaders compete directly and sometimes lead in test, process, meters, and imaging; Chinese OEMs are climbing the value chain in imaging.[7][9]
• Skilled-labor scarcity, not headcount cost. The binding constraint is cleared systems and RF engineers (defense), field-service engineers whose absence idles hospital equipment (irradiation), and calibration technicians and applications engineers (the catch-all) — all in a sector already paying $106,000 on average.[1][3][9][10]
• Concentration and FX. Global sales expose earnings to currency swings, and dependence on a few blockbuster franchises magnifies single-product setbacks.

10. How to invest and the outlook

Public-market routes. Because there is no single instruments ETF, assemble the exposure from the children:

• Defense electronics (334511): aerospace-and-defense primes (RTX, LMT, NOC, GD, LHX, HON) and A&D funds (ITA, PPA, XAR) for broad exposure; focused mid-caps (TDY, DRS, CW, KTOS, MRCY, GRMN) for higher purity and higher beta — the current up-cycle, with record backlogs.[3]
• Health care (334510, 334517): device large-caps (MDT, ABT, GEHC, BSX, JNJ) and focused names (DXCM, MASI, IRTC) for defensive compounding, several paying dividends; imaging and therapy adds GEHC, VREX, ARAY, OSIS, HOLX, XRAY, SHC; IHI and XHE package the device side, though both extend beyond this code.[2][9]
• Industrial measurement (334513, 334515, 334516, 334519, 334514, 334512): diversified serial acquirers (EMR, HON, AME, FTV, RAL, ROP, DHR, TMO, A, ITW, APH, ROK, XYL) for steadier, diluted exposure, or focused pure-plays (KEYS, TER, VIAV, NTCT for test; TMO/DHR/A/WAT/MTD/BRKR/RVTY for labs; BMI/ITRI/MWA for meters; MIR/VPG for detection and precision sensing; TRMB for surveying; REZI/GNRC/WTS for controls; MKSI for process/semiconductor).[4][5][6][7][8][10]
• Funds: aerospace-and-defense, medical-device/health-care-equipment, life-science-tools, water, and broad industrial/automation ETFs each capture one slice of the level — and each carries meaningful non-33451 content, so none is a tracker.

Private-market routes. The private opportunity is consistent across children: venture capital into device, autonomy, and next-generation-instrument startups (exit mostly by strategic acquisition, so timing tracks the majors' M&A appetite); private equity roll-ups of contract manufacturers, calibration and test-lab services, systems integrators, and niche instrument makers prized for sticky, recurring, aftermarket-rich revenue; and direct ownership of the specialists — many of the best franchises (Rohde & Schwarz, Endress+Hauser, KROHNE, VEGA, Diehl, Kamstrup, ZwickRoell, Anton Paar, LECO, Ludlum, BIOTRONIK, Copeland, Danfoss) are private or foreign.[2][4][5][7][8][10] The children converge on the same diligence checklist: separate genuinely recurring revenue from deployment-period maintenance and discretionary replacement; test whether backlog is cancelable; verify certification, accreditation, and export classifications transfer on a change of control; and map sole-source component and single-supplier exposure.[3][4][6][7][10]

Outlook (forward-looking judgment). The level's appeal is precisely that it is a diversified basket of durable, certification-moated, recurring-revenue businesses riding different cycles:

• Up now: defense and sensor demand (allied rearmament, missile defense, counter-drone, resilient PNT) and AI-driven semiconductor and memory test.[3][7]
• Steady: the health-care children (aging demographics, cancer care, the sterilization shift away from ethylene oxide) and utility metering (with water AMI penetration still only about one-third), both anchored to non-discretionary budgets.[2][6][9]
• Muted, with early recovery: analytical labs — soft China, research-funding uncertainty and destocking still weigh, but the sector's revenue turned back up in 2025 and every instrument placement seeds years of consumable annuity, so book-to-bill is the signal to watch.[8] Process control remains cyclical on disciplined oil-and-gas capex and a fab-construction cooldown, offset by data centers, LNG, grid build-outs, and demonstrated pricing power.[5]
• Bifurcated: electrical test, where AI silicon and memory pull one half up while general-purpose, automotive, and EV-exposed lines fall — a reminder that a strong secular theme does not guarantee an even year.[7]
• In transition, with a policy air pocket: environmental controls, moving toward subscription software, grid-flexibility fees, mandated refrigerant-sensor content, and data-center cooling, while losing the 25C credit at the end of 2025 and 179D in mid-2026.[4]

The reliable base case across the whole level is continued portfolio churn — cash-rich acquirers buying innovation while conglomerates split themselves into purer instrument companies — and a steady migration of value from the box to the software and services around it, now measurable in the roughly eight-point gross-margin gap between selling a meter and selling the analytics that run on it.[6] The main offsets are the sector's inherent cyclicality, its patchwork of budget, reimbursement, and policy dependencies with several dated cliffs in 2026 and 2027, and a tariff and supply-chain exposure that is no longer speculative. Net: a defensive-to-cyclical compounding sector — attractive to patient capital on both the public and private sides, best owned with an understanding that its nine parts move to different drummers, and that the federal factory-shipment figure understates how large and global these companies really are. These are informed judgments, not guarantees.

---

Sources

1. Histometrics ingested federal statistics for NAICS 33451 — U.S. Census Bureau, 2022 Economic Census (receipts $168.6B; 4,427 firms; CR4 19.0%, CR8 27.9%, CR20 43.4%, CR50 58.9%; HHI 163.2) and County Business Patterns 2023 (5,050 establishments; 414,694 employees; $44.0B annual payroll). https://www.census.gov/programs-surveys/economic-census.html; https://www.census.gov/programs-surveys/cbp.html
2. Histometrics child primer — NAICS 334510, Electromedical and Electrotherapeutic Apparatus Manufacturing (Economic Census 2022: receipts $39.6B, 822 firms, CR4 28.6%, CR8 40%, CR20 57.8%, HHI 297.6; AIES 2023: sales $45.5B, 94,349 employees, $11.3B payroll; CBP 2023: 892 establishments; U.S. market ~$26.3B in 2024 against HS-9018 exports $35.8B / imports $41.3B; FDA pathways, §524B cyber devices, QMSR effective Feb 2 2026, NTAP/TCET/RAPID; gross margins 40–70%; R&D 6–10%; GE HealthCare $245M tariff hit; J&J–Shockwave). Draws on Census 2022 / CBP 2023 / AIES 2023, SEC filings, FDA and CMS, Grand View Research.
3. Histometrics child primer — NAICS 334511, Search, Detection, Navigation, Guidance, Aeronautical and Nautical Systems and Instruments (receipts $53.5B; 404 firms; 522 establishments; 127,864 employees; $14.3B payroll, ~$112,000 average pay; CR4 57.9%, CR8 78.2%, CR20 90.6%, CR50 96.2%; HHI 1,200; FY2026 national defense $900.6B with ~$295B procurement + RDT&E; book-to-bill ~1.1x in 2024; L3Harris 73% fixed-price; RTX Collins 16.3% margin and $600M charge; Curtiss-Wright Defense Electronics 24.7% margin; Garmin aviation 26% margin; ITAR/EAR/DFARS/CMMC; DHS resilient-PNT guidance). Draws on Census 2022 / CBP 2023, SEC filings, appropriations and CRS data.
4. Histometrics child primer — NAICS 334512, Automatic Environmental Control Manufacturing (Economic Census 2022: receipts ~$3.0B, 207 firms, CR4 40.8%, CR8 56.1%, CR20 74.2%, CR50 90.4%, HHI 602.8; AIES 2023 sales $4.196B; CBP 2023: 233 establishments, 13,458 employees, ~$1.22B payroll; BLS employment 12,965 in 2024 vs 35,549 in 2000; 2002 Census CR4 24.8% / HHI 238.1; Honeywell Building Automation $7.367B at 22.1%; Belimo CHF1.121B and data-center cooling; Copeland/Blackstone ~$14B; JCI–Bosch ~$8.1B; ENERGY STAR, AIM Act/A2L, 25C expiry and 179D termination; DOE 30% HVAC savings). Draws on Census 2022 / CBP 2023 / AIES 2023, BLS, SEC filings, DOE/EPA/EIA.
5. Histometrics child primer — NAICS 334513, Instruments for Measuring, Displaying and Controlling Industrial Process Variables (receipts ~$14.2B; 841 firms; 889 establishments; 39,166 employees; ~$3.39B payroll, ~$87,000 average pay; CR4 27.9%, CR8 36.5%, CR20 50.7%, CR50 68.7%; HHI 297; PPI +6.7% Apr 2025–Apr 2026; Emerson Measurement & Analytical ~$4.14B and Intelligent Devices 23.8% margin; Honeywell Process Solutions ~$6.2B; AMETEK EIG ~$4.66B; Endress+Hauser >€4B, 7.0% R&D, 11.9% margin; IEC 61511, EPA CEMS and the 2024 methane rule, IEC 62443/CISA; global market ~$74–78B). Draws on Census 2022 / CBP 2023, BLS, SEC filings, Mordor/Grand View Research, ARC Advisory.
6. Histometrics child primer — NAICS 334514, Totalizing Fluid Meter and Counting Device Manufacturing (receipts $5.29B; 163 firms; 156 establishments; 11,939 employees; $980.7M payroll, ~$82,000 average pay and ~$443,000 shipments per worker; CR4 32.3%, CR8 49.4%, CR20 73.9%, CR50 93.2%; HHI 422.6; Badger Meter FY2025 $916.7M at ~41.7% gross / ~20.0% operating; Itron FY2025 ~$2.0B with Device 31.2% / Networked 39.1% / Outcomes 39.6% gross margins and ~$4.7B backlog; Xylem M&CS 11.7% margin; ~one-third North American water AMI penetration; EPA $625B need and $50B+ BIL; NSF 61/372, AWWA C700, NIST Handbook 44, NTEP; BABA waiver Dec 2024–Dec 2027). Draws on Census 2022 / CBP 2023, SEC filings, EPA/EIA/GAO/AWWA, Berg Insight via Mordor.
7. Histometrics child primer — NAICS 334515, Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (receipts ~$11.66B; 615 firms; 672 establishments; 29,914 employees; ~$3.49B payroll; CR4 29.3%, CR8 42.9%, CR20 61.7%, CR50 77%; HHI 336; Keysight FY2025 $5.4B at 62.1% gross / 16.3% operating, 19% R&D, services 24% of revenue; Teradyne Semiconductor Test $2.524B up 18.8%; Ralliant T&M $801.5M down 14.5% with $1.44B impairment; Rohde & Schwarz €3.16B private; Emerson–NI $7.8B; ATE ~80% duopoly; NIST traceability / ISO 17025; export controls). Draws on Census 2022 / CBP 2023, BLS, SEC filings, Mordor Intelligence.
8. Histometrics child primer — NAICS 334516, Analytical Laboratory Instrument Manufacturing (receipts $19.35B; 629 firms; 652 establishments; 50,576 employees; $5.74B payroll, ~$113,000 per worker; CR4 25.2%, CR8 40.2%, CR20 60.7%, CR50 78.7%; HHI 273; Thermo Fisher Analytical Instruments $7.55B at 23.0%; Danaher Life Sciences $7.33B; Agilent $6.95B at 52.4% gross / 21.3% operating with 29% services; Waters $3.17B split $1.35B instruments / $632M consumables / $1.19B service; recurring ~80%+ at the majors; Waters–BD ~$17.5B closed Feb 9 2026; NIH FY2025 $48.5B; EPA PFAS Methods 533/537.1; 21 CFR Part 11 and USP <1058>; global market ~$55B with North America ~47%). Draws on Census 2022 / CBP 2023, SEC filings, NIH/EPA/FDA, Grand View Research.
9. Histometrics child primer — NAICS 334517, Irradiation Apparatus Manufacturing (receipts ~$9.18B; 111 firms; 121 establishments; 12,598 employees; ~$1.53B payroll, ~$121,000 per worker and ~$730,000 shipments per worker; CR4 67.5%, CR8 82.2%, CR20 93.4%; HHI ~1,574; GE HealthCare Imaging segment $9.245B in 2025; Varex FY2025 $844.6M at 34.4% gross with a $70M net loss, top-5 customers ~40%; Accuray $458.5M at 32.1%; OSI Systems 34.3%; Elekta SEK 16.7B; Nordion $173M; U.S. imaging top-5 ~96% share; proton therapy ~$1B to ~$2.5B by 2033; sterilization services $2.08B to $4.59B; FDA 21 CFR 1000–1050, MQSA, QMSR; NRC and NNSA CIRP; 61.2M aged 65+; 2.1M new cancer cases in 2026). Draws on Census 2022 / CBP 2023, SEC filings, FDA/NRC/NNSA/NCI, Grand View and Research and Markets.
10. Histometrics child primer — NAICS 334519, Other Measuring and Controlling Device Manufacturing (receipts $12.87B; 789 firms; 913 establishments; 34,818 employees; $3.05B payroll, ~$87,600 average pay; CR4 23.5%, CR8 32.6%, CR20 47.3%, CR50 65.5%; HHI 228.2; watches and clocks added to the code in the 2022 NAICS revision; Mirion FY2025 $925.4M at ~47% gross with $1.1B remaining performance obligations and >80% of nuclear revenue from installed base; VPG $307.2M; FARO $342.4M at 54.7% gross, acquired by AMETEK for ~$920M in July 2025; radiation detection $3.38B in 2024 to $5.45B by 2030; NIST traceability, NRC 10 CFR Part 110, ITAR/EAR; >$10B of tech-company nuclear commitments). Draws on Census 2022 / CBP 2023, SEC filings, NIST/NRC/DoD, MarketsandMarkets.
11. U.S. Small Business Administration, "Table of Small Business Size Standards," NAICS 33451 child codes (600–1,350 employees: 334519 = 600; 334512 = 650; 334513 and 334515 = 750; 334514 = 850; 334516 = 1,000; 334517 = 1,200; 334510 = 1,250; 334511 = 1,350), 2023. https://www.sba.gov/document/support-table-size-standards